Ottolina Davide, Colombo Riccardo, Fossali Tommaso, Castelli Antonio, Rech Roberto, Borghi Beatrice, Ballone Elisabetta, Catena Emanuele
Division of Anesthesiology and Intensive Care, ASST Fatebenefratelli-Sacco, "Luigi Sacco" Hospital, Via G. B. Grassi, 74, 20157, Milan, Italy.
Intern Emerg Med. 2023 Apr;18(3):897-906. doi: 10.1007/s11739-023-03198-8. Epub 2023 Mar 24.
The efficacy of venous-arterial extracorporeal membrane oxygenation (VA-ECMO) in supporting cardio-pulmonary resuscitation for cardiac arrest is still debated. This study aimed to evaluate the outcome of patients treated with VA-ECMO positioned according to different clinical indications. The method is retrospective data analysis from patients admitted to a tertiary referral center for VA-ECMO in 6 years. The study population was divided into three groups based on the VA-ECMO indication: patients with refractory cardiac arrest (CA group), cardiogenic shock after return of spontaneous circulation (CS-ROSC group), and cardiogenic shock without cardiac arrest (CS group). Seventy-nine patients underwent emergency VA-ECMO, 49 patients (62.0%) were in the CA group, 14 (17.7%) in the CS-ROSC group, and 16 patients (20.3%) in the CS group. The overall survival at 28 days was different between the three groups (6.1% in the CA group, 64.2% in the CS-ROSC group, and 50.0% in the CS group, p < 0.001) and remained significant at 12 months (p < 0.001). Furthermore, the Cerebral Performance Category at 12 months differed between groups with good outcomes in 4.1% of patients in CA, 50.0% in CS-ROSC, and 31.2% in CS groups (p < 0.001). In the studied population, emergency VA-ECMO had negligible efficacy in refractory cardiac arrest, while it was correlated with a good outcome in cardiogenic shock after cardiac arrest, such as in cardiogenic shock alone. Patients with ROSC appear to benefit from VA-ECMO in the setting of persistent shock at rates comparable to cardiogenic shock patients who never sustained cardiac arrest.
静脉-动脉体外膜肺氧合(VA-ECMO)在支持心脏骤停的心肺复苏中的疗效仍存在争议。本研究旨在评估根据不同临床指征进行VA-ECMO治疗的患者的结局。方法是对一家三级转诊中心6年内接受VA-ECMO治疗的患者进行回顾性数据分析。根据VA-ECMO指征,研究人群分为三组:难治性心脏骤停患者(CA组)、自主循环恢复后的心源性休克患者(CS-ROSC组)和无心脏骤停的心源性休克患者(CS组)。79例患者接受了紧急VA-ECMO治疗,49例(62.0%)在CA组,14例(17.7%)在CS-ROSC组,16例(20.3%)在CS组。三组患者28天的总体生存率不同(CA组为6.1%,CS-ROSC组为64.2%,CS组为50.0%,p<0.001),12个月时仍有显著差异(p<0.001)。此外,12个月时的脑功能分类在各组之间也有所不同,CA组4.1%的患者、CS-ROSC组50.0%的患者和CS组31.2%的患者预后良好(p<0.001)。在研究人群中,紧急VA-ECMO在难治性心脏骤停中的疗效可忽略不计,而在心脏骤停后的心源性休克中,如单独的心源性休克中,其与良好的预后相关。自主循环恢复的患者在持续性休克情况下似乎从VA-ECMO中获益,其比例与从未发生过心脏骤停的心源性休克患者相当。